Your browser doesn't support javascript.
loading
The development and benefits of metformin in various diseases / 医学前沿
Frontiers of Medicine ; (4): 388-431, 2023.
Artículo en Inglés | WPRIM | ID: wpr-982588
ABSTRACT
Metformin has been used for the treatment of type II diabetes mellitus for decades due to its safety, low cost, and outstanding hypoglycemic effect clinically. The mechanisms underlying these benefits are complex and still not fully understood. Inhibition of mitochondrial respiratory-chain complex I is the most described downstream mechanism of metformin, leading to reduced ATP production and activation of AMP-activated protein kinase (AMPK). Meanwhile, many novel targets of metformin have been gradually discovered. In recent years, multiple pre-clinical and clinical studies are committed to extend the indications of metformin in addition to diabetes. Herein, we summarized the benefits of metformin in four types of diseases, including metabolic associated diseases, cancer, aging and age-related diseases, neurological disorders. We comprehensively discussed the pharmacokinetic properties and the mechanisms of action, treatment strategies, the clinical application, the potential risk of metformin in various diseases. This review provides a brief summary of the benefits and concerns of metformin, aiming to interest scientists to consider and explore the common and specific mechanisms and guiding for the further research. Although there have been countless studies of metformin, longitudinal research in each field is still much warranted.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Envejecimiento / Diabetes Mellitus Tipo 2 / Proteínas Quinasas Activadas por AMP / Hipoglucemiantes / Metformina Límite: Humanos Idioma: Inglés Revista: Frontiers of Medicine Año: 2023 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Envejecimiento / Diabetes Mellitus Tipo 2 / Proteínas Quinasas Activadas por AMP / Hipoglucemiantes / Metformina Límite: Humanos Idioma: Inglés Revista: Frontiers of Medicine Año: 2023 Tipo del documento: Artículo